Jazz EVP has 5,000 shares withheld for taxes

Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported a tax-related share disposition.

Accepted by SEC EDGAR 03/09/2026 - 05:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported a tax-related share disposition. On March 5, 2026, 5,000 Ordinary Shares of Jazz were withheld at $188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. This was recorded as a tax-withholding disposition rather than an open-market sale, and Patil’s directly held stake after the transaction was 53,818 Ordinary Shares.

Insider Trade Summary

Exercise Price or Tax Liability: 5,000 shares

Exercise Price or Tax Liability 1 txn

Insider Patil Neena M

Role EVP & Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	5,000	$188.69	$943K

Holdings After Transaction: Ordinary Shares — 53,818 shares (Direct)

Holdings Before and After: Ordinary Shares, 58,818 to 53,818 shares (Direct)

Footnotes (1)

1. F1. Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Neena M. Patil?

Jazz Pharmaceuticals reported that EVP & Chief Legal Officer Neena M. Patil had 5,000 Ordinary Shares withheld to cover tax obligations from vesting restricted stock units. The transaction was a tax-withholding disposition, not an open-market sale, and reflects routine equity compensation administration.

How many Jazz Pharmaceuticals (JAZZ) shares were involved in Neena Patil’s Form 4 filing?

The Form 4 shows 5,000 Jazz Pharmaceuticals Ordinary Shares were withheld. These shares satisfied tax obligations arising from the vesting of previously granted restricted stock units, as disclosed in the footnote, and did not represent a discretionary buy or sell in the open market.

What price per share was used for the Jazz (JAZZ) tax-withholding disposition?

The tax-withholding disposition for Neena M. Patil’s 5,000 Jazz Pharmaceuticals Ordinary Shares was reported at $188.69 per share. This value is used to calculate the tax coverage amount tied to the vesting of her restricted stock units under the company’s equity compensation arrangements.

How many Jazz Pharmaceuticals (JAZZ) shares does Neena M. Patil hold after this transaction?

After the tax-withholding disposition of 5,000 shares, Neena M. Patil directly holds 53,818 Ordinary Shares of Jazz Pharmaceuticals. This figure reflects her remaining ownership following the withholding tied to restricted stock unit vesting as reported in the Form 4 filing.

Was Neena Patil’s Jazz (JAZZ) transaction an open-market sale or a tax withholding?

Neena Patil’s transaction was a tax withholding, not an open-market sale. The filing states that 5,000 Ordinary Shares were withheld to satisfy tax obligations from vesting restricted stock units, consistent with transaction code F and the accompanying explanatory footnote.

What does transaction code F mean in the Jazz (JAZZ) Form 4 for Neena Patil?

Transaction code F indicates payment of an exercise price or tax liability by delivering securities. In Neena Patil’s case, 5,000 Jazz Pharmaceuticals Ordinary Shares were withheld to cover tax obligations triggered by the vesting of her restricted stock units, as described in the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patil Neena M

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/05/2026		F(1)		5,000	D	$188.69	53,818	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

	By: /s/Paz Dizon, as attorney in fact For: Neena M. Patil	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.